Multiple myeloma: Molecular imaging with 11C-methionine PET/CT - Initial experience

Radiology

Volumn 242, Issue 2, 2007, Pages 498-508

  Dankerl, Anja ^a   Liebisch, Peter ^a   Glatting, Gerhard ^a   Friesen, Claudia ^a   Blumstein, Norbert M ^a   Kocot, Darius ^a   Wendl, Christiane ^a   Bunjes, Donald ^a   Reske, Sven N ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUDARABINE; IOPROMIDE; MELPHALAN; METHIONINE C 11; SULFUR 35; THYMOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; BONE ATROPHY; BONE MARROW; CANCELLOUS BONE; CANCER DIAGNOSIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; MOLECULAR IMAGING; MULTIPLE MYELOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE AND BONES; BONE MARROW; CARBON RADIOISOTOPES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPARATHYROIDISM; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MELPHALAN; METHIONINE; MIDDLE AGED; MULTIPLE MYELOMA; OSTEOLYSIS; PLASMA CELLS; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SULFUR RADIOISOTOPES; SYNDECAN-1; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33846463026     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2422051980     Document Type: Article

References (23)

1. Munshi NC, Anderson KC. Plasma cell neoplasms. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 7th ed. Philadelphia, Pa: Lippincott Williams & Wilkins, 2005.
2. Durie BG, Kyle HA, Belch A, et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003;4:379-398.
3. 18F-FDG PET identifies high-risk myeloma. J Nucl Med 2002;43:1457-1463.
4. Schirrmeister H, Buck AK, Bergmann L, Reske SN, Bommer M. Positron emission tomography (PET) for staging of solitary plasmacytoma. Cancer Biother Radiopharm 2003;18:841-845.
5. Angtuaco EJ, Passas AB, Walker R, Sethi R, Barlogie B. Multiple myeloma: clinical review and diagnostic imaging. Radiology 2004;231:11-23.
6. 18F-FDG PET. Eur J Nucl Med Mol Imaging 2002;29:361-366.
7. Orchard K, Barrington S, Buscombe J, Hilson A, Prentice HG, Metha A. Fluoro-deoxyglucose positron emission tomography imaging for the detection of occult disease in multiple myeloma. Br J Haematol 2002;117:133-135.
8. Bredella MA, Steinbach L, Caputo G, Segall G, Hawkins R. Value of FDG PET in the assessment of patients with multiple myeloma. AJR Am J Roentgenol 2005;184:1199-1204.
9. Moulopoulos LA, Dimopoulos MA, Smith TL, et al. Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 1995;13:251-236.
10. Lecouvet FE, Malghem J, Michaux L, et al. Skeletal survey in advanced multiple myeloma: radiographic versus MR imaging survey. Br J Haematol 1999;106:35-39.
11. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749-757.
12. Liebisch P, Viardot A, Bassermann N, et al. Value of comparative genomic hybridization (CGH) and fluorescence in-situ hybridization (FISH) for molecular diagnostics in multiple myeloma. Br J Haematol 2003;122:193-201.
13. Jego G, Bataille R, Pellat-Decennynck C. Interleukin-6 is a growth factor for nonmalignant human plasmablasts. Blood 2001;97:1817-1822.
14. Comar D, Catron JC, Maziere M, Marazano C. Labelling and metabolism of methioninemethyl-11C. Eur J Nucl Med 1976;1:11-14.
15. Schmid DT, John H, Zweifel R, et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology 2005;235:623-628.
16. Kwee SA, Coel MN, Lim J, Ko JP. Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. J Urol 2005;173:252-255.
17. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998;102:1115-1123.
18. Metz CE. ROC methodology in radiologic imaging. Invest Radiol 1986;21:720-733.
19. Hammerton K, Cooper DA, Duckett M, Penny R. Biosynthesis of immunoglobulin in human immunoproliferative diseases. I. Kinetics of synthesis and secretion of immunoglobulin and protein by bone marrow cells in myeloma. J Immunol 1978;121:409-417.
20. Baur-Melnyk A, Buhmann S, Durr HR, Reiser M. Role of MRI for the diagnosis and prognosis of multiple myeloma. Eur J Radiol 2005;55:56-63.
21. Baur A, Stabler A, Nagel D, et al. Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon? Cancer 2002;95:1334-1345.
22. Mahnken AH, Wildberger JE, Gehbaner G, et al. Multidetector CT of the spine in multiple myeloma: comparison with MR imaging and radiography. AJR Am J Roentgenol 2002;178:1429-1436.
23. Rahmouni A, Montazel JL, Divine M, et al. Bone marrow with diffuse tumor infiltration in patients with lymphoproliferative diseases: dynamic gadolinium-enhanced MR imaging. Radiology 2003;229:710-717.